CL2021003047A1 - Forma cristalina de bromuro de sofpironio y método para su preparación - Google Patents
Forma cristalina de bromuro de sofpironio y método para su preparaciónInfo
- Publication number
- CL2021003047A1 CL2021003047A1 CL2021003047A CL2021003047A CL2021003047A1 CL 2021003047 A1 CL2021003047 A1 CL 2021003047A1 CL 2021003047 A CL2021003047 A CL 2021003047A CL 2021003047 A CL2021003047 A CL 2021003047A CL 2021003047 A1 CL2021003047 A1 CL 2021003047A1
- Authority
- CL
- Chile
- Prior art keywords
- sophironium
- bromide
- crystalline form
- preparation
- diastereomer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/147—Saturated compounds having only one carboxyl group and containing —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrrole Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se proporciona un cocristal que contiene el diastereómero 1'R y el diastereómero 1'S de bromuro de sofpironio en una relación de 1:3 (Forma CO), una mezcla de cristales (por ejemplo, la Forma B) que contiene la Forma CO y una forma cristalina del diastereómero 1'R (Forma MN), y un método para preparar bromuro de sofpironio, que es adecuado para la fabricación de la mezcla de cristales. La Forma CO y una forma cristalina de bromuro de sofpironio que contiene la Forma CO (por ejemplo, la Forma B) tienen una estabilidad superior sin propiedades higroscópicas y, por consiguiente, pueden usarse preferentemente como materia prima de medicamentos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962851880P | 2019-05-23 | 2019-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021003047A1 true CL2021003047A1 (es) | 2022-09-20 |
Family
ID=72146250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021003047A CL2021003047A1 (es) | 2019-05-23 | 2021-11-18 | Forma cristalina de bromuro de sofpironio y método para su preparación |
Country Status (16)
Country | Link |
---|---|
US (3) | US20220298108A1 (es) |
EP (1) | EP3972955A4 (es) |
JP (2) | JP6748329B1 (es) |
KR (1) | KR20220011671A (es) |
CN (1) | CN114008023B (es) |
AU (1) | AU2020277881A1 (es) |
BR (1) | BR112021023241A2 (es) |
CA (1) | CA3139948A1 (es) |
CL (1) | CL2021003047A1 (es) |
CO (1) | CO2021017456A2 (es) |
IL (1) | IL288285A (es) |
MX (1) | MX2021014163A (es) |
SG (1) | SG11202111678WA (es) |
TW (2) | TWI838531B (es) |
WO (1) | WO2020235665A1 (es) |
ZA (1) | ZA202109514B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4002383A3 (en) | 2020-11-13 | 2022-08-03 | Tokyo Institute of Technology | Information processing device, information processing method, recording medium recording information processing program, and information processing system |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
JP5257073B2 (ja) * | 2005-11-10 | 2013-08-07 | ボーダー、ニコラス・エス | ソフト型抗コリン作動性エステル |
US7399861B2 (en) * | 2005-11-10 | 2008-07-15 | Bodor Nicholas S | Soft anticholinergic esters |
MX357741B (es) * | 2012-07-06 | 2018-07-23 | Laboratorios Senosiain S A De C V Star | Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5. |
US9512166B2 (en) * | 2012-09-05 | 2016-12-06 | Amri Ssci, Llc | Cocrystals of progesterone |
US20150259283A1 (en) * | 2014-03-13 | 2015-09-17 | Brickell Biotech, Inc. | Formulation for soft anticholinergic analogs |
US10906871B2 (en) * | 2016-08-02 | 2021-02-02 | Dermira, Inc. | Processes for making, and methods of using, glycopyrronium compounds |
-
2020
- 2020-05-22 JP JP2020089283A patent/JP6748329B1/ja active Active
- 2020-05-22 MX MX2021014163A patent/MX2021014163A/es unknown
- 2020-05-22 EP EP20809754.3A patent/EP3972955A4/en active Pending
- 2020-05-22 SG SG11202111678WA patent/SG11202111678WA/en unknown
- 2020-05-22 WO PCT/JP2020/020210 patent/WO2020235665A1/en active Application Filing
- 2020-05-22 TW TW109117164A patent/TWI838531B/zh active
- 2020-05-22 CA CA3139948A patent/CA3139948A1/en active Pending
- 2020-05-22 US US17/611,158 patent/US20220298108A1/en active Pending
- 2020-05-22 AU AU2020277881A patent/AU2020277881A1/en active Pending
- 2020-05-22 CN CN202080034880.8A patent/CN114008023B/zh active Active
- 2020-05-22 BR BR112021023241A patent/BR112021023241A2/pt unknown
- 2020-05-22 KR KR1020217041385A patent/KR20220011671A/ko unknown
- 2020-05-22 TW TW112144978A patent/TW202411205A/zh unknown
- 2020-08-06 JP JP2020133620A patent/JP2020189856A/ja active Pending
- 2020-11-25 US US17/105,376 patent/US11566000B2/en active Active
-
2021
- 2021-06-30 US US17/364,445 patent/US11584715B2/en active Active
- 2021-11-18 CL CL2021003047A patent/CL2021003047A1/es unknown
- 2021-11-21 IL IL288285A patent/IL288285A/en unknown
- 2021-11-24 ZA ZA2021/09514A patent/ZA202109514B/en unknown
- 2021-12-20 CO CONC2021/0017456A patent/CO2021017456A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020235665A1 (en) | 2020-11-26 |
CA3139948A1 (en) | 2020-11-26 |
US20210395197A1 (en) | 2021-12-23 |
US11566000B2 (en) | 2023-01-31 |
TW202411205A (zh) | 2024-03-16 |
JP2020189856A (ja) | 2020-11-26 |
IL288285A (en) | 2022-01-01 |
EP3972955A4 (en) | 2023-07-05 |
ZA202109514B (en) | 2023-12-20 |
JP2020189839A (ja) | 2020-11-26 |
AU2020277881A1 (en) | 2021-12-09 |
SG11202111678WA (en) | 2021-11-29 |
TWI838531B (zh) | 2024-04-11 |
CN114008023A (zh) | 2022-02-01 |
MX2021014163A (es) | 2022-01-04 |
CO2021017456A2 (es) | 2022-01-17 |
US20220298108A1 (en) | 2022-09-22 |
JP6748329B1 (ja) | 2020-08-26 |
US20210171460A1 (en) | 2021-06-10 |
TW202110796A (zh) | 2021-03-16 |
EP3972955A1 (en) | 2022-03-30 |
BR112021023241A2 (pt) | 2022-01-04 |
KR20220011671A (ko) | 2022-01-28 |
CN114008023B (zh) | 2024-02-09 |
US11584715B2 (en) | 2023-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20210504A (es) | Compuestos tricíclicos condensados útiles como agentes anticancerígenos | |
PH12020551870A1 (en) | Tetracyclic heteroaryl compounds | |
CY1123689T1 (el) | Κρυσταλλικη μορφη ελευθερης βασης λορλατινιβης | |
ECSP17007538A (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
AR113782A1 (es) | Preparación y almacenamiento de formulaciones de arn liposomal adecuadas para tratamiento | |
WO2016172496A8 (en) | Lsd1 inhibitors and uses thereof | |
MX2019015744A (es) | Composiciones farmaceuticas. | |
GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
BR112017004448A2 (pt) | uso de agente de reforço de receptor gabaa na preparação de medicamento sedativo e anestésico | |
AR071788A1 (es) | Derivados de 3-aminocarbazol, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos para tratar y/o prevenir trastornos asociados con la produccion de prostaglandina e2(pge2), tales como aterosclerosis, artritis, artrosis y tumores, entre otros. | |
PH12018500377A1 (en) | Novel annelated benzamides | |
CY1126141T1 (el) | Κρυσταλλικη μορφη του υδριτη ελευθερης βασης λορλατινιμπης | |
UY36651A (es) | Compuestos antiestrogénicos | |
AR068187A1 (es) | Forma cristalina de un intermediario sintetico para la preparacion de un inhibidor de dpp-iv | |
AR083484A1 (es) | Mezcla de fosfato para fabricar un cemento de alta resistencia, composicion, suspension de cemento y metodo para fabricar un producto cementoso | |
UY34854A (es) | Inhibidores del transporte de glucosa | |
MX2018009500A (es) | Sal de maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus metodos de preparacion y usos de la sal de maleato y formas cristalinas. | |
MY194711A (en) | Novel annelated phenoxyacetamides | |
CL2021003047A1 (es) | Forma cristalina de bromuro de sofpironio y método para su preparación | |
PH12019500681A1 (en) | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof | |
PE20141049A1 (es) | Composicion farmaceutica antihipertensiva | |
WO2018125880A8 (en) | Nrf2 activator | |
CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
MX2018001735A (es) | Compuestos espirocíclicos de fumagillol y compuestos bicíclicos fusionados y métodos de elaboración y uso de los mismos. | |
MX2016004963A (es) | Sal y formas cristalinas de inhibidores de quinasa tipo polo-4. |